GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Inventories, Other

BioLine Rx (BioLine Rx) Inventories, Other : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. BioLine Rx's other inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.

BioLine Rx's quarterly other inventories increased from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($1.35 Mil) but then declined from Sep. 2023 ($1.35 Mil) to Dec. 2023 ($0.00 Mil).


BioLine Rx Inventories, Other Historical Data

The historical data trend for BioLine Rx's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Inventories, Other Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1.35 -

BioLine Rx Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


BioLine Rx (BioLine Rx) Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.